Thomas Crisman Email & Phone Number

Tirschenreuth, Bavaria, DE

I am currently the lead scientist helping to develop, improve and use a proprietary pipeline designed to determine treatment courses for people with a variety of cancers using NGS data. The selected drug(s) are then approved or turned down by a panel of oncologists. I believe thanks to our data mining approaches we currently have the best available data in.

San Francisco, California, US

Los Angeles, CA, US

• Postdoctoral Researcher, Bioinformatics/Personalized Medicine, Psychiatry
• Developed method of variable reduction in random forest models designed to be used to create reduced panels of biomarkers to predict clinical phenotypes or outcomes. This is helpful in both reducing the way we look at.
• Using the largest existing library of stem cell cultures produced from tumors, made breakthroughs in the characterization of these cultures using various machine learning methods and biostatistics approaches on a.
• Designed and developed an algorithm for strain selection that doubled the cost effectiveness of our admixture mapping experiments in pre-built backcross libraries of inbred mouse strains like the collaborative cross.
• Admixture mapping of a neuroregenerative phenotype in inbred mouse strains using snvs, methylation and RNA-seq data (manuscript under preparation).

• Created an experimentally validated (by Förster resonance energy transfer and Crystallography) alternative protein confirmation of GltPh, proving that not only is it likely that family of transporters came about.

• Designed and created a method of breaking apart docking scores and applying scores to 2D molecular features of known biologically active molecules for use in compound cherry picking, library design in high throughput.

Basel, Baselstadt, CH

• Developed new approach to link data from fragment based small molecule high throughput screening (low molecular weight compounds) in order to combine the fragments into a molecules that fit the characteristics expected.

Basel, Baselstadt, CH

• Developed a new method of triaging hit-lists in cell-based assays based on the prediction of off target effects in small molecules (Crisman et al. JCIM). This was part of a larger ongoing project within my group that.
• Developed a new method of more efficient deck screening when a limited amount of enzyme/cell is available, making it possible to find 66% of the hits and 75% of the chemical scaffolds by screening only a quarter of the.

Phd, Biomathematics, Bioinformatics, And Computational Biology

Master Of Science - Ms, Bioinformatics

Bachelor Of Science - Bs, Chemistry